Apolipoprotein C3 (APOC3) Antibody
299€ (100 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Apolipoprotein C3 (APOC3) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx131732
tested applications
WB, IHC, IF/ICC
Description
Apolipoprotein C3 Antibody is a Mouse Monoclonal against Apolipoprotein C3.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Apolipoprotein C3 (APOC3) |
| Host | Mouse |
| Reactivity | Rat |
| Recommended Dilution | WB: 0.01-5 µg/ml, IHC: 5-30 µg/ml, IF/ICC: 5-30 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Isotype | IgG2b Kappa |
| Purification | Purified by Protein A and Protein G affinity chromatography. |
| Size 1 | 100 µl |
| Size 2 | 200 µl |
| Size 3 | 1 ml |
| Form | Liquid |
| Tested Applications | WB, IHC, IF/ICC |
| Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Shipped within 5-7 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | P06759 |
| Alias | APOC3, APOCIII, HALP2, apolipoprotein C3, Apo-C3, ApoC-3,apo-CIII, and apolipoprotein C-III |
| Background | Antibody anti-APOC3 |
| Status | RUO |
Descripción
APOC3 is a critical regulator of triglyceride-rich lipoprotein (TRL) metabolism, primarily associated with VLDL, HDL, and chylomicrons. APOC3 inhibits lipoprotein lipase (LPL) and hepatic uptake of remnant lipoproteins by interfering with the binding of TRLs to heparan sulfate proteoglycans (HSPG) and the low-density lipoprotein receptor (LDLR). Elevated APOC3 levels are strongly associated with hypertriglyceridemia, atherogenic dyslipidemia, and increased risk of cardiovascular disease. APOC3 expression is regulated by dietary factors, insulin, and nuclear receptors such as PPAR-alpha. Loss-of-function mutations in the APOC3 gene result in lower plasma triglycerides and reduced cardiovascular risk, highlighting its potential as a therapeutic target for lipid disorders. APOC3 also modulates inflammatory responses and has been implicated in non-alcoholic fatty liver disease (NAFLD), where elevated levels contribute to hepatic lipid accumulation. Pharmacological inhibitors of APOC3, such as antisense oligonucleotides, are being developed to lower plasma triglycerides and improve lipid profiles in hyperlipidemic patients.
Related Products
Human APOC3 (Apolipoprotein C-III) ELISA Kit
Ver Producto
Recombinant Human APOC3
Ver Producto